Feb. 2, 2012
("Vista") announced today that it published its FREE monthly newsletter for the month of February. Each monthly newsletter from Vista contains macroeconomic thoughts from its Principal Analyst,
, and monthly highlights of each covered company.
In the February Newsletter,
, Principal Analyst at Vista Partners states the following regarding ADVENTRX Pharmaceutical, Inc. (NYSE Amex: ANX), "ADVENTRX seems to be bouncing back from year-end tax loss selling and it seems investors are focused on the initiation of two Phase 3 trials scheduled to begin this year. ANX currently trades at a negative enterprise value which means its market cap is less than it cash position. It seems that little to no value is being given to the Company's two late stage clinical candidates. This would seem to make absolutely no sense and we doubt the opportunity to purchase shares of ADVENTRX for less than the company's cash value per share will last for much longer especially considering both Phase 3 trials are fully funded to completion."
To download the FREE February Newsletter, please visit
and click the "download newsletter" icon to gain access.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of
. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of
profitable investment ideas
Please remember to follow us on Twitter @VistaPResearch &
at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more ...
Disclaimer & Disclosure:
We encourage readers to view a complete list of disclaimers and disclosures on our website